Navigation Links
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
Date:9/17/2008

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the United States. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.

SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild-type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an effective treatment for other hematological malignancies with mutations and re-arrangements in the JAK2 gene.

"The entry of SB1518 into the clinical phase marks an important milestone for S*BIO and potentially offers a new targeted therapy for this group of difficult-to-treat patients that represent a significant unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518 has demonstrated exciting anti-proliferative and anti-tumor activity, combined with excellent tolerability in relevant in vitro and in vivo models. We are pleased to conduct our company's first clinical trials in the United States at well respected centers such as The University of Texas M.D. Anderson Cancer Center, the University of Chicago Medical Center and the Fred Hutchinson Cancer Research Center."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is currently in Phase I trials in Singapore and Canada. S*BIO's target-driven approach to developing innovative small molecule therapies for cancer is built on a profound unde
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
4. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
5. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
6. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
7. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
8. Isis Initiates Clinical Trial of CRP Drug
9. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
10. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Stryker Orthopaedics, the Official Joint Replacement ... rounding out its debut year of the relationship at ... AZ. This marks the eleventh tournament stop ... the brand has activated on-site with the "Stryker Mobility ... on the importance of joint health.  ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
(Date:10/30/2014)... Mass. , Oct. 30, 2014 Boston ... to participate in the 2014 Credit Suisse Annual Healthcare ... Phoenix , AZ.  Dan Brennan , executive ... presentation about the company beginning at approximately 8:00 a.m. ... A live webcast of the presentation and question ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2
... Conn., Sept. 16 Amarin Corporation plc (Nasdaq: ... is scheduled to present on Amarin,s behalf at the Global ... 12:30 pm. This conference will be held at the Grand ... appointed as President and Chief Executive Officer, will also be ...
... Wis., Sept. 16 Top researchers at the Gastrointestinal ... Dallas are exploring the clinical applications of BCM-95®, a ... bioavailability. Previous studies have shown that ... forms of curcumin, and had a retention time in ...
Cached Medicine Technology:Amarin to Present at UBS Life Sciences Conference 2BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2
(Date:10/30/2014)... Chicago, October 30, 2014—Analysis of data from an ... indicates excellent long-term, local control, 79 percent of ... patients treated with SBRT from 2003 to 2012, ... Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium ... Oncology (ASCO), the American Society for Radiation Oncology ...
(Date:10/30/2014)... Beach, Florida (PRWEB) October 30, 2014 ... Halloween visit to Pompano Beach firefighters, showing that you ... community. , Timothy met firefighters Tracey and Carl ... by Galuppi’s Restaurant and the Pompano Beach Chamber of ... outside the fire truck, letting Timothy wear his real ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... Fort Lauderdale, FL (PRWEB) October 30, 2014 ... leading US Joint Commission Accredited teleradiology and specialty ... today that in addition to its existing teleradiology ... adding multispecialty second opinion and expert telemedicine services, ... Houston, Texas. , As a result of this ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3
... it was found that triple drug therapy helped people suffer ... a clot-preventing drug such as aspirin, an ACE inhibitor for ... that these drugs work synergistically to reduce the amount of ... a neurologist at Harvard Medical School and co-director of the ...
... that women who drink insufficient milk during pregnancy probably to ... inhibit// their babies’ growth in the womb. ,The ... Association Journal. 300 women took part in the study. All ... babies of mothers who drank at least a cup of ...
... to lead can induce hypertension in lab animals and more ... adults too. But till now nothing concrete was known about ... to expose to lead for five years researchers have found ... ,Lead's most widely documented effects are neurological. Exposure ...
... will become the benchmark against which the growth of babies ... from the practice of almost 4 decades, //where babies have ... growth pattern portrayed by formula- fed babies. ,It ... rate as compared to breast fed infants and this makes ...
... the American Civil Liberties Union are questioning the policy ... and customs agents to detain travelers //who look like ... is reportedly available with Reuters, also allows Customs and ... ,Health and Human Services Secretary ...
... the advertisement on junk foods shown on television poses ... by tempting them to go for it thereby leading ... foodconsumer.org, previous studies have already associated childhood overweight with ... link between childhood overweight and TV viewing is due ...
Cached Medicine News:Health News:Limiting milk can hamper Babies’ Growt 2Health News:Exposure To Lead Doesn’t Cause Hypertension In Childre 2Health News:Junk Food Ads: The Culprit Behind Childhood Obesity 2
... day surgery and post anesthesia care in one ... is a high performance monitor designed for the ... and induction rooms. It offers the flexibility of ... advanced airway gas monitoring. When paired with the ...
... The complete picture of patient respiration and ... the most versatile respiration and ventilation monitors available. ... models. Each model allows you to measure the ... O 2 , and N 2 O easily ...
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: